Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu
Trial record 1 of 1 for:    HMR-1002
Previous Study | Return to List | Next Study

AAVCAGsCD59 for the Treatment of Wet AMD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03585556
Recruitment Status : Completed
First Posted : July 13, 2018
Last Update Posted : May 25, 2022
Information provided by (Responsible Party):
Janssen Research & Development, LLC

Brief Summary:
Patients with treatment naive wet AMD will receive an intravitreal anti-VEGF injection at Day 0 followed by an intravitreal injection of AAVCAGsCD59 at Day 7. Patients will be followed monthly through Month 12 and receive an intravitreal anti-VEGF injection as needed based on an increase in central subfoveal thickness (CST) of >50 micrometers on OCT from Day 0, new subretinal hemorrhage on clinical exam, and/or loss of 10 or more ETDRS letters from the previous month exam.

Condition or disease Intervention/treatment Phase
Wet Age-related Macular Degeneration Drug: Intravitreal anti-VEGF Biological: Intravitreal AAVCAGsCD59 Drug: Oral prednisolone Phase 1

Detailed Description:

This is a Phase 1, multi-center, open label study to assess the efficacy and safety of two doses of the adeno-associated viral vector serotype 2 (AAVCAGsCD59) expressing sCD59 administered via intravitreal injection seven days after a single intravitreal injection of anti-VEGF. All patients considered for enrollment in this study must have treatment naive wet AMD, adequate pupillary dilation to permit a thorough ocular exam, and best corrected distance visual acuity in the study eye of 20/25 to 20/400 using the Snellen eye chart.

Written informed consent will be obtained from each study patient prior to his/her participation in any study related procedures. Screening will determine patient eligibility for the study according to written inclusion and exclusion criteria, which include both general medical and AMD-specific criteria. Patients will be enrolled into the study upon verification that they fulfill all eligibility criteria and after completion of all screening assessments.

This study consists of a screening and injection of anti-VEGF (Day 0), injection of AAVCAGsCD59 (Day 7), and a monthly follow-up period (Month 1 through Month 12) where enrolled patients are treated as needed with intravitreal anti-VEGF based on an increase in central subfoveal thickness of >50 micrometers on OCT from Day 0, new subretinal hemorrhage, a decrease in > or equal to 10 ETDRS letters from the previous exam, or as needed based on the treating clinician. The purpose of the study is to evaluate the number of anti-VEGF injections that are required after a single intravitreal injection of AAVCAGsCD59 at a dose of 3.56x10e11vg for subjects 1-22 and 1.071x10e12vg for subjects 23-25 is administered on Day 7. Anti-VEGF will be injected at Day 0 to treat the CNV per standard of care and enable the AAVCAGsCD59 adequate time (up to two weeks) to enter the ganglion cells in the retina and start producing the transgene product, sCD59. Up to twenty-five (25) patients will be enrolled at to 2 clinical sites in this study. A long-term follow-up safety exam will occur at Month 24.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: All patients with treatment naive, new onset wet AMD will be treated with an intravitreal anti-VEGF at Day 0 followed by intravitreal AAVCAGsCD59 at Day 7. Patients will be followed for 12 months and treated with additional anti-VEGF monthly as needed if recurrent disease is identified.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Proof of Concept Study Evaluating Intravitreal AAVCAGsCD59 for the Treatment of Wet Age-Related Macular Degeneration (AMD)
Actual Study Start Date : September 13, 2018
Actual Primary Completion Date : January 29, 2020
Actual Study Completion Date : January 18, 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: AAVCAGsCD59 Treated Arm
An anti-VEGF injection will be given at Day 0 followed by an intravitreal injection of AAVCAGsCD59 at Day 7. All eyes will then be treated with intravitreal anti-VEGF monthly as needed based on disease activity.
Drug: Intravitreal anti-VEGF
Intravitreal injection of anti-VEGF at Day 0 then monthly as needed
Other Names:
  • Bevacizumab (Avastin)
  • Ranibizumab (Lucentis)
  • Aflibercept (Eylea)

Biological: Intravitreal AAVCAGsCD59
An intravitreal injection of AAVCAGsCD59 will occur at Day 7 once
Other Name: HMR59

Drug: Oral prednisolone
A 7 day tapering dose of oral prednisone will be taken at Day 30 by all patients
Other Name: oral corticosteroid

Primary Outcome Measures :
  1. Number of intravitreal anti-VEGF injections [ Time Frame: 12 months ]
    Measure the number of intravitreal anti VEGF injections from Month 1 through Month 12 following an intravitreal injection of AAVCAGsCD59 at Day 7

Secondary Outcome Measures :
  1. Number of patients with change in vision of ≥ 15 letters [ Time Frame: 12 months ]
    Evaluate the change in vision in eyes receiving intravitreal AAVCAGsCD59 in conjunction with anti VEGF for new onset wet AMD

  2. Number of patients with inflammation, endophthalmitis, IOP>30, retinal detachment, cataract, and systemic adverse events [ Time Frame: 24 months ]
    Evaluate SAEs associated with the use of intravitreal AAVCAGsCD59

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Men or women 50 years of age or older.
  2. Treatment naive Wet AMD with no evidence of subretinal fibrosis under the fovea.
  3. Presence of intraretinal and/or subretinal fluid on OCT.
  4. Best corrected visual acuity (BCVA) Snellen equivalent 20/25 to 20/400 in the study eye using ETDRS charts at a starting distance of 4m.
  5. Adequate pupillary dilation to permit ocular examination and testing.
  6. Ability and willingness to return for all scheduled visits and assessments.
  7. Understand and comply with the clinical protocol and provide written informed consent prior to any study-related procedure.
  8. All fertile men must be willing to use barrier contraception during the study.
  9. Women of childbearing potential must have a negative pregnancy test and agree to use effective contraception for the duration of the trial. A woman of childbearing potential is defined as any female who has had menses within the last two years or has not undergone a hysterectomy or surgical sterilization.

Exclusion Criteria:

  1. Wet AMD secondary to non-AMD etiologies.
  2. Subretinal hemorrhage that interferes with the ability to adequately measure visual acuity or follow retinal or subretinal fluid collection on OCT.
  3. Serous pigment epithelial detachment (PED) that is >50% of the CNV lesion, >400µm in any diameter, or presence of a RPE tear.
  4. Presence of polypoidal choroidal vasculopathy (PCV), retinal angiomatous proliferation (RAP), central serous retinopathy, or symptomatic vitreomacular adhesion.
  5. Previous macular laser photocoagulation for CNV, photodynamic therapy (PDT), ocular radiation, or subretinal surgery for CNV in the study eye.
  6. History of conditions in the study eye which might alter visual acuity or interfere with study testing including clinically significant macular edema, central retinal vein occlusion, macular branch retinal vein occlusion, and optic neuropathy.
  7. Active uncontrolled glaucoma with IOP>30 mmHg despite treatment with glaucoma medications, cup-to-disc ratio of >0.9, visual field defects secondary to glaucoma that involve the macula, and optic atrophy from glaucoma.
  8. Likely candidate for intraocular surgery (including cataract surgery) in the study eye during the clinical trial.
  9. Acute or chronic infection in the study eye.
  10. History of uveitis unrelated to eye surgery in the study eye or opposite eye requiring treatment with topical corticosteroids or systemic immunosuppression within 24 months of enrollment.
  11. Any contraindication to intravitreal injection.
  12. Use intravitreal (study eye) corticosteroids within 3 months prior to screening.
  13. Any of the following underlying systemic diseases:

    • Unstable or severe cardiovascular disease, e.g., congestive heart failure (New York Heart Association Functional class III or IV), myocardial infarction within 6 months, ventricular tachyarrhythmias requiring ongoing treatment, unstable angina, or critical limb ischemia;
    • Cerebrovascular disease within 12 months prior to Screening that impairs the patient's ability to participate in the clinical trial;
    • Dementia or neurodegenerative disease (e.g., Alzheimer's disease, Parkinson's disease) of a level that prevents adequate evaluation of the subject during the study;
    • Has an active malignancy or is currently undergoing treatment for an active malignancy at Screening, or has a history of malignancy that precludes completion of this 12-month study;
    • Immunocompromised conditions and/or need for immunosuppressive therapy
  14. Any significant poorly controlled illness that would preclude study compliance and follow-up
  15. Current or prior use of any medication known to be toxic to the retina or optic nerve including, but not limited, to chloroquine/hydrochloroquine, deferoxamine, phenothiazines and ethambutol
  16. Previous treatment with any ocular or systemic gene transfer product
  17. Received any investigational product within 120 days prior to screening
  18. Any psychological, familial, sociological, geographical, or other condition that would preclude study compliance and follow-up

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03585556

Layout table for location information
United States, Massachusetts
Ophthalmic Consultants of Boston
Boston, Massachusetts, United States, 02114
Vitreo-Retina Associates
Worcester, Massachusetts, United States, 01605
Sponsors and Collaborators
Janssen Research & Development, LLC
Layout table for additonal information
Responsible Party: Janssen Research & Development, LLC Identifier: NCT03585556    
Other Study ID Numbers: 81201887MDG1002
HMR-1002 ( Other Identifier: Janssen Research & Development, LLC )
81201887MDG1002 ( Other Identifier: Janssen Research & Development, LLC )
First Posted: July 13, 2018    Key Record Dates
Last Update Posted: May 25, 2022
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Janssen Research & Development, LLC:
Wet Age-related Macular Degeneration
Gene therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal